Business
Interim Results for the period ended 30 June 2020
Interim Results for the period ended 30 June 2020.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5079A\n Hemogenyx Pharmaceuticals PLC\n 30 September 2020\n \n \n \n \n 30 September 2020\n \n \n \n \n \n \n \n \n Hemogenyx Pharmaceuticals plc\n \n \n (\"Hemogenyx Pharmaceuticals\" or \"the Company\")\n \n \n \n \n \n Half-year Report\n \n \n Interim Results for the period ended 30 June 2020\n \n \n \n \n \n Hemogenyx Pharmaceuticals plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces unaudited interim results for the six-month period ended 30 June 2020.\n \n \n \n \n \n All financial amounts are stated in GBP British pounds unless otherwise indicated.\n \n \n \n \n \n Key highlights\n \n \n \n \n \n CAR-T cells\n \n \n · \n Successfully constructed Chimeric Antigen Receptor (CAR) programmed T cells (\"HEMO-CAR-T\") for the potential treatment of Acute Myeloid Leukemia (AML) and tested in vitro and in vivo\n \n \n · \n Post period end, entered into a Sponsored Research Agreement with the University of Pennsylvania to advance HEMO-CAR-T toward clinical trials; the agreement is envisaged as the first step of a larger programme that aims to achieve clinical proof of concept for HEMO-CAR-T for the treatment of AML\n \n \n \n \n \n CDX bi-specific antibodies\n \n \n · \n Extended development agreement with a leading global pharmaceutical company (\"GlobalCo\") to finalise manufacturability work and successfully bring CDX bi-specific antibody to a state of readiness for pre-clinical development\n \n \n · \n Discussions regarding a potential licensing deal are continuing with GlobalCo following the extension of the Development Agreement\n \n \n \n \n \n COVID-19 Project\n \n \n · \n Deployment of groundbreaking research capabilities and technologies to develop treatments for COVID-19: using its humanised mice the Company seeks to discover human neutralising antibodies that could be used to fight SARS-CoV-2 infections, the virus that causes COVID-19\n \n \n \n \n \n Autoimmune diseases\n \n \n · \n Entered into an agreement with Eli Lilly and Company in June 2020 to perform research and development activities aimed at the discovery and validation of novel materials to be used for the treatment of Lupus \n \n \n \n \n \n Human Postnatal Hemogen...